Insights from the early experience of the society of thoracic surgeons/American college of cardiology transcatheter valve therapy registry

John S. Rumsfeld, David Holmes, Wendy Gattis Stough, Fred H. Edwards, Louis B. Jacques, Michael J. Mack

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The current system for postmarket surveillance of medical devices in the United States is limited. To help change this paradigm for transcatheter valve therapies (TVTs), starting with transcatheter aortic valve replacement, the Society of Thoracic Surgeons and the American College of Cardiology partnered to form the TVT Registry program in close collaboration with the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services. The goal of the TVT Registry is to measure and improve quality of care and patient outcomes in clinical practice and to have a pivotal role in the scientific evidence and surveillance for medical devices. Challenges were faced in the early experience of the registry included developing multistakeholder partnerships, data collection requirements, and the use of the registry for pre- and post-market device evaluations. In addressing these challenges, the TVT Registry demonstrates that it is feasible for professional societies to assume a pivotal role in pre- and/or post-market studies, leveraging a clinical registry infrastructure. Sharing the TVT Registry experience may help other professional societies and stakeholders better anticipate and plan for these challenges.

Original languageEnglish (US)
Pages (from-to)377-381
Number of pages5
JournalJACC: Cardiovascular Interventions
Volume8
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Cardiology
Registries
Thorax
Equipment and Supplies
Therapeutics
Centers for Medicare and Medicaid Services (U.S.)
Quality of Health Care
United States Food and Drug Administration
Surgeons

Keywords

  • Centers for Medicare and Medicaid Services (U.S.)
  • heart valve prosthesis implantation
  • investigational device exemption
  • National Cardiovascular Data Registry
  • registries
  • transcatheter aortic valve replacement
  • U.S. Food and Drug Administration

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Insights from the early experience of the society of thoracic surgeons/American college of cardiology transcatheter valve therapy registry. / Rumsfeld, John S.; Holmes, David; Stough, Wendy Gattis; Edwards, Fred H.; Jacques, Louis B.; Mack, Michael J.

In: JACC: Cardiovascular Interventions, Vol. 8, No. 3, 01.03.2015, p. 377-381.

Research output: Contribution to journalReview article

Rumsfeld, John S. ; Holmes, David ; Stough, Wendy Gattis ; Edwards, Fred H. ; Jacques, Louis B. ; Mack, Michael J. / Insights from the early experience of the society of thoracic surgeons/American college of cardiology transcatheter valve therapy registry. In: JACC: Cardiovascular Interventions. 2015 ; Vol. 8, No. 3. pp. 377-381.
@article{245b76b831fe4d1eb4233e6d3c8509d0,
title = "Insights from the early experience of the society of thoracic surgeons/American college of cardiology transcatheter valve therapy registry",
abstract = "The current system for postmarket surveillance of medical devices in the United States is limited. To help change this paradigm for transcatheter valve therapies (TVTs), starting with transcatheter aortic valve replacement, the Society of Thoracic Surgeons and the American College of Cardiology partnered to form the TVT Registry program in close collaboration with the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services. The goal of the TVT Registry is to measure and improve quality of care and patient outcomes in clinical practice and to have a pivotal role in the scientific evidence and surveillance for medical devices. Challenges were faced in the early experience of the registry included developing multistakeholder partnerships, data collection requirements, and the use of the registry for pre- and post-market device evaluations. In addressing these challenges, the TVT Registry demonstrates that it is feasible for professional societies to assume a pivotal role in pre- and/or post-market studies, leveraging a clinical registry infrastructure. Sharing the TVT Registry experience may help other professional societies and stakeholders better anticipate and plan for these challenges.",
keywords = "Centers for Medicare and Medicaid Services (U.S.), heart valve prosthesis implantation, investigational device exemption, National Cardiovascular Data Registry, registries, transcatheter aortic valve replacement, U.S. Food and Drug Administration",
author = "Rumsfeld, {John S.} and David Holmes and Stough, {Wendy Gattis} and Edwards, {Fred H.} and Jacques, {Louis B.} and Mack, {Michael J.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.jcin.2014.09.022",
language = "English (US)",
volume = "8",
pages = "377--381",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Insights from the early experience of the society of thoracic surgeons/American college of cardiology transcatheter valve therapy registry

AU - Rumsfeld, John S.

AU - Holmes, David

AU - Stough, Wendy Gattis

AU - Edwards, Fred H.

AU - Jacques, Louis B.

AU - Mack, Michael J.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - The current system for postmarket surveillance of medical devices in the United States is limited. To help change this paradigm for transcatheter valve therapies (TVTs), starting with transcatheter aortic valve replacement, the Society of Thoracic Surgeons and the American College of Cardiology partnered to form the TVT Registry program in close collaboration with the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services. The goal of the TVT Registry is to measure and improve quality of care and patient outcomes in clinical practice and to have a pivotal role in the scientific evidence and surveillance for medical devices. Challenges were faced in the early experience of the registry included developing multistakeholder partnerships, data collection requirements, and the use of the registry for pre- and post-market device evaluations. In addressing these challenges, the TVT Registry demonstrates that it is feasible for professional societies to assume a pivotal role in pre- and/or post-market studies, leveraging a clinical registry infrastructure. Sharing the TVT Registry experience may help other professional societies and stakeholders better anticipate and plan for these challenges.

AB - The current system for postmarket surveillance of medical devices in the United States is limited. To help change this paradigm for transcatheter valve therapies (TVTs), starting with transcatheter aortic valve replacement, the Society of Thoracic Surgeons and the American College of Cardiology partnered to form the TVT Registry program in close collaboration with the U.S. Food and Drug Administration and the Center for Medicare and Medicaid Services. The goal of the TVT Registry is to measure and improve quality of care and patient outcomes in clinical practice and to have a pivotal role in the scientific evidence and surveillance for medical devices. Challenges were faced in the early experience of the registry included developing multistakeholder partnerships, data collection requirements, and the use of the registry for pre- and post-market device evaluations. In addressing these challenges, the TVT Registry demonstrates that it is feasible for professional societies to assume a pivotal role in pre- and/or post-market studies, leveraging a clinical registry infrastructure. Sharing the TVT Registry experience may help other professional societies and stakeholders better anticipate and plan for these challenges.

KW - Centers for Medicare and Medicaid Services (U.S.)

KW - heart valve prosthesis implantation

KW - investigational device exemption

KW - National Cardiovascular Data Registry

KW - registries

KW - transcatheter aortic valve replacement

KW - U.S. Food and Drug Administration

UR - http://www.scopus.com/inward/record.url?scp=84926415787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926415787&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2014.09.022

DO - 10.1016/j.jcin.2014.09.022

M3 - Review article

C2 - 25703888

AN - SCOPUS:84926415787

VL - 8

SP - 377

EP - 381

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 3

ER -